When patients ask about weight loss medications, Ozempic is usually the first word out of their mouth. That's reasonable; it's become the household name. But the GLP-1 landscape has expanded significantly over the past few years, and the right drug for a given patient depends on factors that simple brand recognition misses. Here's a clinical view of what's actually available, how I think about the choices, and what matters beyond picking a name.
How GLP-1 medications work
GLP-1 receptor agonists mimic a gut hormone your body releases after meals. They slow gastric emptying, reduce appetite, and improve insulin sensitivity. Newer agents add additional hormone targets (GIP, glucagon) to the mix, which can produce greater weight loss at the cost of some additional side effects.
The drugs now in regular use or available in the near future:
- Semaglutide (Ozempic, Wegovy, Rybelsus). The best-studied option. Average weight loss in trials around 12 to 15 percent. Rybelsus is the oral version, less bioavailable than injection but useful for patients who can't or won't inject.
- Tirzepatide (Mounjaro, Zepbound). Dual GIP/GLP-1 agonist. Typically produces greater weight loss than semaglutide (15 to 20 percent or more in trials), with a similar side effect profile though sometimes more GI symptoms during titration.
- Retatrutide. Triple-action (GLP-1, GIP, glucagon), still in Phase 3. Trial data has been notable, with some patients losing over 24 percent of body weight. Not yet FDA-approved; expected in the next year or two.
- Liraglutide (Saxenda, Victoza). Daily injection, older agent. Less weight loss than semaglutide or tirzepatide. Still appropriate for some patients.
- CagriSema. Combination of semaglutide and cagrilintide (an amylin analog). Showing strong efficacy in trials; may be available soon.
Each has its place. The choice depends on your goals, your tolerance for side effects, your clinical picture, and increasingly, what insurance will cover.
How I approach the choice with patients
In my practice, this conversation takes real time, not the seven minutes you might get in a traditional visit.
First, clarify the goal. Are you primarily treating type 2 diabetes with weight loss as a secondary benefit? Treating obesity without diabetes? Maintaining weight loss you've already achieved? The answers shape both medication choice and dosing strategy.
Second, review the medical history carefully. Personal or family history of medullary thyroid cancer or MEN2 syndrome is an absolute contraindication. History of pancreatitis warrants careful consideration. Active gastroparesis is a significant concern. Pregnancy or active attempts to conceive require stopping. These screens matter.
Third, talk realistically about side effects. Nausea, constipation, sometimes vomiting. Worst during dose titration, typically easing over weeks. Patients need to know what to expect and how to manage it. Starting low and titrating slowly makes a significant difference in tolerability.
Fourth, discuss the long view. These drugs work because they address the biology of appetite and satiety. That biology doesn't go away when you stop the drug. Most patients who stop regain weight. The realistic framing is usually a long-term commitment, not a short course.
The medical supervision issue
Online clinics prescribing these medications after a brief questionnaire have become common. I've seen patients come in after obtaining medications this way with complications that appropriate monitoring would have prevented.
GLP-1 medications should include:
- Regular check-ins during titration and ongoing treatment
- Periodic lab work to monitor kidney function, liver function, and nutritional markers
- Monitoring for gallbladder issues, pancreatitis symptoms, or significant muscle loss
- Assessment of nutritional status; rapid weight loss without adequate protein and nutrient intake causes sarcopenia
- Review of other medications, particularly any that affect gastric motility or that might interact
- Counseling for patients undergoing surgery or anesthesia, since these drugs affect gastric emptying
None of this is exotic. It's the kind of monitoring appropriate for any potent medication.
Why the medication alone isn't enough
GLP-1 drugs work best as part of a broader approach. The results I see in my patients who do this well include not just weight loss but improvements in blood pressure, sleep apnea severity, joint pain, exercise tolerance, and cardiovascular risk markers. For patients treated as though the drug were a standalone solution, weight regain after stopping is the usual pattern.
What actually matters alongside the medication:
- Adequate protein intake to preserve muscle mass during weight loss (usually 1.2 to 1.6 grams per kg of ideal body weight)
- Resistance training to maintain and build muscle
- Aerobic exercise for cardiovascular and metabolic benefit
- Sleep optimization, which affects appetite regulation directly
- Realistic expectations about the speed and trajectory of weight loss
- A plan for the maintenance phase, including whether and how the medication transitions
If you're considering a GLP-1
If you're thinking about one of these medications, find a physician who will take time to work through your full picture: medical history, goals, risk factors, current medications, and what realistic supervised treatment looks like. Close monitoring beats brand-name recognition every time.
If you'd like to talk through whether a GLP-1 makes sense for your specific situation, or you're currently on one and want more attentive oversight than you're getting, reach out.
This post is educational and not medical advice. Any medication decision should involve a real conversation with your physician.
